Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Clinical trial NCT06040320 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06040320
- Sponsor
- Washington University School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-04
- Primary completion
- 2027-05-31
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.